CBMG completes Wuxi stem cell plant expansion
The firm has added 20,000 square feet of manufacturing space at the facility and installed technologies for the production of plasmids and viral vectors, as well as a cell bank and laboratory for the development of reagents.
CEO Tony Liu said: “We have long recognized the logistical challenges of delivering consistent, quality and clinical grade processes to deliver cell therapies to market and we have differentiated our capabilities to meet this challenge.
“We will now be able to centralize, standardize and automate our manufacturing capabilities fully in-house while enhancing our capacity to meet the production demands of multiple products in development as part of our overall Chemistry, Manufacturing, and Controls process.”
In January, Beijing-based CBMG leased a building at the Zhangjiang High-Tech Park in Shanghai and announced its intention to build a cell manufacturing plant.
The firm said: “By the end of 2017, the Company anticipates that the combination of this Wuxi site, the new Zhangjiang Shanghai and the Beijing GMP facilities will be capable of supporting simultaneous clinical trials for five different CAR-T and stem cell products.”
